Malignant astrocytoma in elderly patients: where do we stand?

被引:4
作者
Tabatabai, Ghazaleh [1 ]
Stupp, Roger [2 ]
Wick, Wolfgang [3 ,4 ]
Weller, Michael [1 ]
机构
[1] Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Dept Med Oncol, CH-8091 Zurich, Switzerland
[3] Univ Heidelberg Hosp, Dept Neurooncol, German Canc Res Ctr DKFZ, German Canc Consortium DKTK,Natl Ctr Tumor Dis, Heidelberg, Germany
[4] Univ Heidelberg Hosp, Neurol Clin, German Canc Res Ctr DKFZ, German Canc Consortium DKTK, Heidelberg, Germany
关键词
clinical trial; elderly patients; malignant astrocytoma; molecular signature; GLIOBLASTOMA-MULTIFORME; PHASE-II; RADIATION-THERAPY; OLDER PATIENTS; TEMOZOLOMIDE; RADIOTHERAPY; SURVIVAL; BEVACIZUMAB; IDH1; NORMALIZATION;
D O I
10.1097/WCO.0000000000000037
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose of review Age is inversely correlated with clinical outcome and a strong prognostic factor for the course of most primary brain tumors including malignant astrocytoma, i.e. anaplastic astrocytoma and glioblastoma. We here review available clinical outcome data and discuss future directions of clinical research. Recent findings The standard of care in patients with malignant astrocytoma above the range of 65-70 years was considered radiotherapy, preferentially using a hypofractionated regimen (15 x 2.66 Gy). Two phase III clinical trials, the NOA-08 and Nordic trials, demonstrated that temozolomide (TMZ) therapy alone was not inferior to radiotherapy alone, and methylation of the O-6-methylguanine-DNA-methyltransferase (MGMT) gene promoter was predictive with a methylated MGMT promoter indicating a benefit from TMZ chemotherapy. Ongoing clinical trials in this patient population include the National Cancer Institute of Canada/European Organisation for Research and Treatment of Cancer intergroup trial, investigating the combination of hypofractionated radiotherapy and TMZ chemotherapy, and the Swiss ARTE trial, investigating the combination of bevacizumab and hypofractionated radiotherapy. Recent translational studies indicate that prognostically favorable factors in malignant astrocytoma from younger patients are virtually absent in the elderly. Summary Current standard of care for elderly patients with malignant astrocytoma involves a treatment strategy based on the MGMT gene promoter methylation status. The role of combined radiotherapy and TMZ chemotherapy and a potential role for the addition of anti-VEGF therapy to radiotherapy are currently addressed in ongoing trials. The lack of favorable prognostic factors in tumor tissue might in part explain the poorer clinical outcome of elderly patients.
引用
收藏
页码:693 / 700
页数:8
相关论文
共 35 条
  • [1] Treatment for primary CNS lymphoma: The next step
    Abrey, LE
    Yahalom, J
    DeAngelis, LM
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3144 - 3150
  • [2] Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
    Agnihotri, Sameer
    Gajadhar, Aaron S.
    Ternamian, Christian
    Gorlia, Thierry
    Diefes, Kristin L.
    Mischel, Paul S.
    Kelly, Joanna
    McGown, Gail
    Thorncroft, Mary
    Carlson, Brett L.
    Sarkaria, Jann N.
    Margison, Geoffrey P.
    Aldape, Kenneth
    Hawkins, Cynthia
    Hegi, Monika
    Guha, Abhijit
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (01) : 253 - 266
  • [3] Comprehensive genomic characterization defines human glioblastoma genes and core pathways
    Chin, L.
    Meyerson, M.
    Aldape, K.
    Bigner, D.
    Mikkelsen, T.
    VandenBerg, S.
    Kahn, A.
    Penny, R.
    Ferguson, M. L.
    Gerhard, D. S.
    Getz, G.
    Brennan, C.
    Taylor, B. S.
    Winckler, W.
    Park, P.
    Ladanyi, M.
    Hoadley, K. A.
    Verhaak, R. G. W.
    Hayes, D. N.
    Spellman, Paul T.
    Absher, D.
    Weir, B. A.
    Ding, L.
    Wheeler, D.
    Lawrence, M. S.
    Cibulskis, K.
    Mardis, E.
    Zhang, Jinghui
    Wilson, R. K.
    Donehower, L.
    Wheeler, D. A.
    Purdom, E.
    Wallis, J.
    Laird, P. W.
    Herman, J. G.
    Schuebel, K. E.
    Weisenberger, D. J.
    Baylin, S. B.
    Schultz, N.
    Yao, Jun
    Wiedemeyer, R.
    Weinstein, J.
    Sander, C.
    Gibbs, R. A.
    Gray, J.
    Kucherlapati, R.
    Lander, E. S.
    Myers, R. M.
    Perou, C. M.
    McLendon, Roger
    [J]. NATURE, 2008, 455 (7216) : 1061 - 1068
  • [4] Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations
    Chinot, OL
    Barrie, M
    Frauger, E
    Dufour, H
    Figarella-Branger, D
    Palmari, J
    Braguer, D
    Hoang-Xuan, K
    Moktari, K
    Peragut, JCC
    Martin, PMM
    Grisoli, F
    [J]. CANCER, 2004, 100 (10) : 2208 - 2214
  • [5] Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma
    Christians, Arne
    Hartmann, Christian
    Benner, Axel
    Meyer, Jochen
    von Deimling, Andreas
    Weller, Michael
    Wick, Wolfgang
    Weiler, Markus
    [J]. PLOS ONE, 2012, 7 (03):
  • [6] Downregulation of PRDX1 by promoter hypermethylation is frequent in 1p/19q-deleted oligodendroglial tumours and increases radio- and chemosensitivity of Hs683 glioma cells in vitro
    Dittmann, L. M.
    Danner, A.
    Gronych, J.
    Wolter, M.
    Stuehler, K.
    Grzendowski, M.
    Becker, N.
    Bageritz, J.
    Goidts, V.
    Toedt, G.
    Felsberg, J.
    Sabel, M. C.
    Barbus, S.
    Reifenberger, G.
    Lichter, P.
    Tews, B.
    [J]. ONCOGENE, 2012, 31 (29) : 3409 - 3418
  • [7] Gilbert M., 2011, J CLIN ONCOL S, P29
  • [8] Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
    Hartmann, Christian
    Hentschel, Bettina
    Wick, Wolfgang
    Capper, David
    Felsberg, Joerg
    Simon, Matthias
    Westphal, Manfred
    Schackert, Gabriele
    Meyermann, Richard
    Pietsch, Torsten
    Reifenberger, Guido
    Weller, Michael
    Loeffler, Markus
    von Deimling, Andreas
    [J]. ACTA NEUROPATHOLOGICA, 2010, 120 (06) : 707 - 718
  • [9] Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
    Jain, RK
    [J]. SCIENCE, 2005, 307 (5706) : 58 - 62
  • [10] Characterization of Molecular Genetic Alterations in GBMs Highlights a Distinctive Molecular Profile in Young Adults
    Jha, Prerana
    Suri, Vaishali
    Singh, Geetika
    Jha, Pankaj
    Purkait, Suvendu
    Pathak, Pankaj
    Sharma, Vikas
    Sharma, Mehar Chand
    Suri, Ashish
    Gupta, Deepak
    Mahapatra, Ashok Kumar
    Sarkar, Chitra
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 2011, 20 (04) : 225 - 232